NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2024 and provided a business update.
Acumen Pharmaceuticals reported a net loss of $20.5 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $281.4 million as of June 30, 2024, which is expected to support operations into the first half of 2027. The company is actively enrolling subjects in ALTITUDE-AD, a Phase 2 study, and dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024.
- Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease.
- Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025.
- Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, expected to support current clinical and operational activities into the first half of 2027.
- The company plans to host a virtual R&D Day on Oct. 2, 2024, providing a deep dive into the scientific rationale, Phase 1 clinical results and Phase 2 clinical plans for sabirnetug.
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2024
+0.6%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-6.4%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.3% | -9.8% | — | |
| Q1 2026 | -3.5% | -11.7% | -7.8% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro